PolandTuberculosis profile
Population  2015 39 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.54 (0.52–0.57) 1.4 (1.4–1.5)
Mortality (HIV+TB only) 0.019 (<0.01–0.093) 0.05 (0–0.24)
Incidence  (includes HIV+TB) 7.2 (6.2–8.3) 19 (16–21)
Incidence (HIV+TB only) 0.14 (0.11–0.18) 0.37 (0.28–0.46)
Incidence (MDR/RR-TB)** 0.07 (0.049–0.091) 0.18 (0.13–0.24)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.28 (0.18–0.39) 2 (1.3–2.8) 2.3 (1.4–3.2)
Males 0.26 (0.18–0.35) 4.6 (3.6–5.6) 4.8 (3.8–5.9)
Total 0.55 (0.42–0.68) 6.6 (6–7.2) 7.2 (6.2–8.3)
TB case notifications, 2015  
Total cases notified 6 430
Total new and relapse 6 237
          - % tested with rapid diagnostics at time of diagnosis 12%
          - % with known HIV status <1%
          - % pulmonary 94%
          - % bacteriologically confirmed among pulmonary 76%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.08 (0.07–0.09)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  60
(42–79)
Estimated % of TB cases with MDR/RR-TB 0.66% (0.42–0.98) 3.7% (2.1–5.9)  
% notified tested for rifampicin resistance 65% 63% 4 177
MDR/RR-TB cases tested for resistance to second-line drugs   9
Laboratory-confirmed cases MDR/RR-TB: 44, XDR-TB: 3
Patients started on treatment **** MDR/RR-TB: 34, XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 58% 6 500
Previously treated cases, excluding relapse, registered in 2014 49% 149
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 22% 46
XDR-TB cases started on second-line treatment in 2013 0% 1
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data